Acrivon Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Acrivon Therapeutics, Inc. (ACRV) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 6.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-27
- Acrivon Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 6.00%, a 36.36% increase from fiscal 2023.
- Acrivon Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 4.40%, a 238.46% increase from fiscal 2022.
- Acrivon Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 1.30%, a 333.33% increase from fiscal 2021.
- Acrivon Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 0.30%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 6.00% 10-K · filed 2025-03-27 |
| 2023-12-31 | 4.40% 10-K · filed 2025-03-27 |
| 2022-12-31 | 1.30% 10-K · filed 2024-03-28 |
| 2021-12-31 | 0.30% 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |